Table 2. Characteristics of included studies.
| NO. | Study | Animal model | (Mice/Rat) | Tol-DC(Number)(total number) | Controls | Outcomes | DC(R/D) | ||||||
| C1 | C2 | O1 | O2 | O3 | O4 | O5 | |||||||
| Untreated | Negative | SUR | MLR | CK | Treg | CTL | |||||||
| A1 | * Stepkowsk(2006)1 | (D)H-2b | (R)H-2d | (T)H-2k | Bioreactor-imDC(Balb/c) (5) | √ | >150d | / | / | Y | / | R-DC | |
| Bioreactor-imDC(Balb/cStat4−/−) (5) | >150d | ||||||||||||
| Totle | MHC total mismatch: n = 1 | Monotherapy: n = 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | R-DC:n = 1 | |||
| Combination: n = 1 | D-DC:n = 0 | ||||||||||||
| B1 | Olakunle(2001)11 | (D)RT-1u | (R)RT-1a | (T)RT-1n | P5-BMDC(10∧6,i.v.) (5) | √ | ↑ | Y | / | / | / | R-DC | |
| P5-BMDC+ALS(2*10∧6,i.v.) (5) | >200d | ||||||||||||
| P5-BMDC(2*10∧6,i.v.) (4) | ↑ | ||||||||||||
| P5-BMDC+ALS(10∧6,i.t.) (11) | >200d | ||||||||||||
| P5-thymic DC(5*10∧6,i.v.) (4) | ↑ | ||||||||||||
| P5-thymic DC+ALS(5*10∧6,i.v.) (4) | >200d | ||||||||||||
| B2 | Ali(2000)12 | (D)RT-1u | (R)RT-1a | (T)RT-1n | P5-DC+ALS(-) (5) | √ | √ | ↑ | Y | / | / | / | R-DC |
| P5-DC+ALS(0.5 ml) (5) | ↑ | ||||||||||||
| B3 | Oluwole(1995)13 | (R)RT-1u | (D)RT-1l | (T)RT-1n | D-Ag+DC(R) (3) | √ | √ | ↑ | Y | / | / | / | R/D-DC |
| D-Ag+DC(D) (4) | - | ||||||||||||
| Totle | MHC total mismatch: n = 3 | Monotherapy: n = 3 | 3 | 2 | 3 | 3 | 0 | 0 | 0 | R-DC:n = 3 | |||
| Combination: n = 2 | D-DC:n = 1 | ||||||||||||
| C1 | Yang(2008)2 | (R)H-2b | (D)H-2d | CTLA-4Ig-DC(8) | √ | √ | ↑ | Y | TH2 | / | / | / | |
| C2 | Zhu(2008)3 | (R)H-2b | (D)H-2d | IL10-DC(8) | √ | √ | ↑ | Y | TH2 | / | / | R-DC | |
| C3 | O'Rourke(2000)4 | (R)H-2b | (D)H-2d | (T)H-2k | D2SC/1-CTLA4-Ig (10) | √ | √ | ↑ | Y | / | / | / | D-DC |
| D2SC/1-CTLA4-Ig (additional injection) | - | ||||||||||||
| C4 | & Li(2010)5 | / | / | rAd-DCR3-DC | √ | √ | ↑ | / | / | / | Y | / | |
| rAd-GAD65/DCR3-DC | ↑ | ||||||||||||
| Totle | MHC total mismatch: n = 3 | Monotherapy: n = 4 | 4 | 4 | 4 | 3 | 2 | 0 | 1 | R-DC:n = 1 | |||
| Combination: n = 0 | D-DC:n = 1 | ||||||||||||
| D1 | Hauben(2008)6 | (D)H-2b | (R)H-2d | mDC-VAF347 (17) | √ | √ | ↑ | Y | TH2 | Y | / | R-DC | |
| imDC+VAF347 (19) | - | ||||||||||||
| mDC (14) | - | ||||||||||||
| imDC (18) | - | ||||||||||||
| Totle | MHC total mismatch: n = 1 | Monotherapy: n = 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | R-DC:n = 1 | |||
| Combination: n = 0 | D-DC:n = 0 | ||||||||||||
| E1 | & Huang(2010)7 | (R)H-2b | (D)H-2d | R-KSC+D-DC | √ | √ | ↑ | Y | - | - | / | R/D-DC | |
| R-KSC+R-DC | - | ||||||||||||
| Totle | MHC total mismatch: n = 1 | Monotherapy: n = 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | R-DC:n = 1 | |||
| Combination: n = 0 | D-DC:n = 1 | ||||||||||||
| F1 | Kim(2006)8 | (R)H-2b | (D)H-2d | (T)H-2k | CD4+imDC+anti-CD154Ab (6) | √ | √ | >120d | Y | TH2 | Y | / | D-spleen DC |
| CD4+imDC+antiCD154Ab+anti-IL10R Ab(4) | >120d | ||||||||||||
| CD4+imDC (6) | - | ||||||||||||
| CD8+imDC (6) | - | ||||||||||||
| CD8+imDC+anti-CD154Ab (6) | - | ||||||||||||
| F2 | Rastellini(1995)9 | (R)H-2b | (D)H-2k | liver-imDC(10) | √ | √ | ↑ | Y | / | / | / | D-liver DC | |
| spleen-imDC (4) | - | ||||||||||||
| F3 | Chaib(1994)10 | (D)RT-1u | (R)RT-1l | DC+ALS (9) | √ | - | / | / | / | / | D-spleenDC | ||
| NPC+ALS (8) | - | ||||||||||||
| Totle | MHC total mismatch: n = 3 | Monotherapy: n = 3 | 3 | 2 | 3 | 2 | 1 | 1 | 0 | R-DC:n = 0 | |||
| Combination: n = 1 | D-DC:n = 3 | ||||||||||||
A1: Immature dendritic cells (imDC) group. B1–3: Allopeptide-pulsed group. C1–4: Gene modification group. D1: Drug intervention group. E1: Mesenchymal stem cell (MSC) induction group. F1–3: Other derived group.
“&” Articles did not report the sample size. “/” Articles did not report relevant information. “-” No difference between experiment group and control group.
H-2b: C57. H-2d: BAL/C. H-2k: C3H. RT-1u: WF/WAG. RT-1a: ACI. RT-1n: BN. RT-1l: Lewis.
D: Donor. R: Recipient. T: The third party. MHC: Major histocompatibility complex. BMDC: Bone marrow dendritic cell. Ag: Antigen. R-KSC: Host kidney-derived MSC. NPCs: Non-parenchymal cells. ALS: Anti-lymphocyte serum. P5: MHC Class I peptide five. D-DC: Donor-derived DC. R-DC: Recipient-derived DC. SUR: Survival, “↑” Prolongation. MLR: Mixed lymphocyte reaction, “Y” Successfully induced donor specific T cell hyporesponsiveness. CK: Cytokine. CTL: Cytotoxic T lymphocyte, “Y” Reduced cytotoxicity against allografts. Treg: Regulatory T cells, “Y” Successfully induced Treg.